Tumor-derived SAA1-TLR4 signaling drives tumor-to-muscle communication in pancreatic cancer cachexia

Gabriele Guarnaccia Jimmy Massenet Alessandra Cecchini E. Guarnaccia Beatrice Silvestri C. Nicoletti J. R. Barajas D. Sala M. Teneche Brightany Li Luca Caputo Ceda Stamenkovic Tatiana M. Moreno Rabi Murad Shawn Delaware Daphne Mayer Yi-Juan Zhang Priyanka Gupta Alexandre R. Colas A. Vasciaveo Caroline Kumsta Peter D. Adams W. Wang C. Gargioli Commisso Cosimo P. L. Puri Alessandra Sacco

Sep 2026 · bioRxiv · 0 citations

Biology

TL;DR

Conservation of SAA1-TLR4 signaling in human skeletal muscle identifies a therapeutically actionable tumor–host pathway and demonstrates that host deterioration can be targeted independently of tumor progression.

DOI Semantic Scholar

View source

Similar papers

#protein folding Sep 2026

Abstract A062: SFRP2 Silencing Restrains Pancreatic Cancer Growth and Enhances Survival Through Remodeling of the Tumor Microenvironment

Findings identify SFRP2 as a key regulator of PDAC progression and support the development of SFRP2-targeted therapies as a novel treatment strategy for pancreatic cancer.

Olivia Sweatt, Lillian Hsu, Lety Reyes Angeles et al. · Cancer Research · 0 citations

Sep 2026

Abstract B101: Stroma-tumor crosstalk converges with oncogenic KRAS signaling to drive an NFκB-mediated immune evasion program

An immunosuppressive tumor microenvironment (TME) is a hallmark of pancreatic ductal adenocarcinoma (PDAC), rendering most tumors resistant to immunotherapy approaches. Importantly, “tumor-to-stroma” crosstalk downstream of oncogenic KRAS has emerged as a major driver of immune evasion in PDAC, however the role of re...

Yuwenbin Li, Morgan L. Truitt, Dan Cao et al. · Cancer Research · 0 citations

Sep 2026

Abstract B001: Cancer-associated fibroblast p38α MAPK signaling coordinates collagen architecture and immune suppression to drive chemoresistance in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) remains highly refractory to chemoimmunotherapy due in large part to its dense, immunosuppressive stroma. Cancer-associated fibroblasts (CAFs), the dominant stromal cell population, promote tumor progression through inflammatory signaling, aligned collagen-rich extracellula...

Camille Acevedo, Sayan Chakraborty, Samara P. Singh et al. · Cancer Research · 0 citations

Sep 2026

Abstract B099: Tumor progression locus 2 kinase drives pancreatic cancer immune evasion through a MYBL2-CXCL10 signaling axis

Pancreatic ductal adenocarcinoma (PDAC) is characterized by a chronically inflamed tumor microenvironment (TME) driven by persistent activation of innate inflammatory signaling. Tumor progression locus 2 (TPL2; MAP3K8) is a serine/threonine kinase downstream of KRAS that activates both MAPK and NF-κB signaling; howev...

Hua-Ping Li, Yu-Tong Geng, Hung-Han Huang et al. · Cancer Research · 0 citations

Aug 2026

LTBP4 deficiency induces MRC1+/CD44+ macrophages to drive cancer progression in preclinical colorectal cancer models.

This study positions LTBP4 as a key modulator of tumor progression and reveals a therapeutic strategy for LTBP4-deficient CRC.

Songtao Ji, Shuya Du, Ge Miao et al. · Science Translational Medici... · 0 citations

Open access Sep 2026

A microbial chromatin remodeler drives gastric cancer progression and immune evasion by reprogramming the host epigenome.

First-line treatment for gastric cancer (GC) includes PD-1 blockade with chemotherapy, but resistance challenges treatment success. We identify Streptococcus anginosus (SA) as a tumor-resident oncobacterium driving GC progression and immune evasion. SA is enriched in GC patient tumors and drives tumor growth in mice. S...

Xiao-Shan Xie, Yue Wei, Jia-Ying Zheng et al. · Cell Host and Microbe · 0 citations